Svenningsson P - Search Results

1

Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.

Markaki I, Ntetsika T, Sorjonen K, Svenningsson P; BioPark Study Group. Markaki I, et al. Among authors: svenningsson p. Mov Disord. 2021 Jun;36(6):1430-1434. doi: 10.1002/mds.28545. Epub 2021 Feb 26. Mov Disord. 2021. PMID: 33634916

2

Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.

Svenningsson P, Westman E, Ballard C, Aarsland D. Svenningsson P, et al. Lancet Neurol. 2012 Aug;11(8):697-707. doi: 10.1016/S1474-4422(12)70152-7. Lancet Neurol. 2012. PMID: 22814541 Review.

3

Initial cognitive decline is associated with cortical thinning in early Parkinson disease.

Pereira JB, Svenningsson P, Weintraub D, Brønnick K, Lebedev A, Westman E, Aarsland D. Pereira JB, et al. Among authors: svenningsson p. Neurology. 2014 Jun 3;82(22):2017-25. doi: 10.1212/WNL.0000000000000483. Epub 2014 May 7. Neurology. 2014. PMID: 24808018 Free PMC article.

4

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.

Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF. Svenningsson P, et al. Mov Disord. 2016 Sep;31(9):1422-3. doi: 10.1002/mds.26734. Epub 2016 Jul 19. Mov Disord. 2016. PMID: 27431803 No abstract available.

5

Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A. Fazio P, et al. Among authors: svenningsson p. Mov Disord. 2018 Apr;33(4):592-599. doi: 10.1002/mds.27316. Epub 2018 Feb 13. Mov Disord. 2018. PMID: 29436751 Clinical Trial.

6

Eye movements during reading in Parkinson's disease: A pilot study.

Waldthaler J, Tsitsi P, Seimyr GÖ, Benfatto MN, Svenningsson P. Waldthaler J, et al. Among authors: svenningsson p. Mov Disord. 2018 Oct;33(10):1661-1662. doi: 10.1002/mds.105. Epub 2018 Oct 8. Mov Disord. 2018. PMID: 30298615 No abstract available.

7

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Green H, Tsitsi P, Markaki I, Aarsland D, Svenningsson P. Green H, et al. Among authors: svenningsson p. CNS Drugs. 2019 Feb;33(2):143-160. doi: 10.1007/s40263-018-0601-x. CNS Drugs. 2019. PMID: 30687888 Free PMC article. Review.

8

Decreased Cerebrospinal Fluid Aβ42 in Patients with Idiopathic Parkinson's Disease and White Matter Lesions.

Markaki I, Klironomos S, Svenningsson P. Markaki I, et al. Among authors: svenningsson p. J Parkinsons Dis. 2019;9(2):361-367. doi: 10.3233/JPD-181486. J Parkinsons Dis. 2019. PMID: 30714972

9

First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L.

Hertz E, Thörnqvist M, Holmberg B, Machaczka M, Sidransky E, Svenningsson P. Hertz E, et al. Among authors: svenningsson p. Mov Disord Clin Pract. 2019 Mar 7;6(3):254-258. doi: 10.1002/mdc3.12743. eCollection 2019 Mar. Mov Disord Clin Pract. 2019. PMID: 30949558 Free PMC article.

10

Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease.

Green HF, Khosousi S, Svenningsson P. Green HF, et al. Among authors: svenningsson p. J Parkinsons Dis. 2019;9(4):705-709. doi: 10.3233/JPD-191699. J Parkinsons Dis. 2019. PMID: 31524180 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

460 results

Search Page

Filters